TIDMHCM

RNS Number : 1580B

Hutchmed (China) Limited

30 September 2022

Total Voting Rights

Hong Kong, Shanghai, & Florham Park, NJ - Friday, September 30, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at September 30, 2022, the issued share capital of HUTCHMED consisted of 864,775,340 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 864,775,340 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For illustrative purposes only, the 864,775,340 ordinary shares would be equivalent to 864,775,340 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 172,955,068 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,900 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has advanced 13 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President        +852 2121 8200 
  Annie Cheng, Vice President            +1 (973) 567 3786 
 
Media Enquiries 
  Americas - Brad Miles, Solebury        +1 (917) 570 7340 (Mobile) | bmiles@soleburystrat.com 
  Europe - Ben Atwell / Alex Shaw, FTI   +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) | 
                                         HUTCHMED@fticonsulting.com 
  Asia - Zhou Yi, Brunswick              +852 97 83 6894 (Mobile) | HUTCHMED@brunswickgroup.com 
 
Nominated Advisor 
  Atholl Tweedie / Freddy Crossley, 
   Panmure Gordon (UK) Limited           +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRDZGZLRLGGZZG

(END) Dow Jones Newswires

September 30, 2022 04:30 ET (08:30 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Hutchison China Meditech
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Hutchison China Meditech